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The metabolic syndrome (MetS) is a cluster of cardiometabolic disorders that result from the increasing prevalence of obesity. The
major components of MetS include insulin resistance, central obesity, dyslipidemia, and hypertension. MetS identifies the central
obesity with increased risk for cardiovascular diseases (CVDs) and type-2 diabetes mellitus (T2DM). Patients with rheumatic
diseases, such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, and ankylosing spondylitis, have increased
prevalence of CVDs.Moreover, CVD risk is increased when obesity is present in these patients. However, traditional cardiovascular
risk factors do not completely explain the enhanced cardiovascular risk in this population. Thus, MetS and the altered secretion
patterns of proinflammatory adipokines present in obesity could be the link between CVDs and rheumatic diseases. Furthermore,
adipokines have been linked to the pathogenesis of MetS and its comorbidities through their effects on vascular function and
inflammation. In the present paper, we review recent evidence of the role played by adipokines in the modulation of MetS in the
general population, and in patients with rheumatic diseases.
1. Introduction
The metabolic syndrome (MetS) is a cluster of cardiomet-
abolic disorders that result from the increasing prevalence
of obesity. The major components of MetS include insulin
resistance, central obesity, dyslipidemia, and hypertension
[1]. It is widely accepted that the concept ofMetS identifies the
central obesity with increased risk for cardiovascular diseases
(CVDs) and type-2 diabetes mellitus (T2DM) [2, 3]. Never-
theless, it still lacks a universally accepted definition. Various
diagnostic criteria have been proposed by different orga-
nizations over the past decade, thus giving five definitions
for MetS [4–8]. Recently, the International Diabetes Feder-
ation (IDF) and the American Heart Association/National
Heart, Lung, and Blood Institute (AHA/NHLBI) have devel-
oped one unified definition [9]. Several rheumatic diseases
(rheumatoid arthritis (RA), osteoarthritis (OA), systemic
lupus erythematosus (SLE), and ankylosing spondylitis (AS))
have been associated with an increase in the prevalence of
CVDs. Though traditional cardiovascular risk factors (sex,
smoking, dyslipidemia, age, and hypertension) have been
involved in the pathogenesis of CVDs in patients with
rheumatic diseases, these features do not completely explain
the enhanced cardiovascular risk in this population [10]. For
instance, CVDs are responsible for almost 50% excess ofmor-
tality in patients with RA [11, 12]. Furthermore, the incidence
of CVDs is increased when obesity is present in patients
with rheumatic disorders. Evidence now indicates that MetS
begins with excess of central adiposity [13]. Thus, MetS and
obesity, in particular, pathologic dysfunction of fat mass, due
to altered secretion patterns of proinflammatory adipokines,
could be the link between CVDs and rheumatic diseases [14,
15]. Adipose tissue is now recognized as an endocrine organ
able to secrete adipose-derived factors named adipokines.
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Adipokines have been linked to the pathogenesis ofMetS and
its comorbidities through their effects on vascular function
and inflammation [14, 16, 17]. The present paper reviews
recent lines of evidence of the role played by adipokines
produced by adipose tissue in the modulation of MetS in the
general population and in patients with rheumatic diseases.
2. Metabolic Syndrome and
Rheumatic Diseases
Patients with chronic rheumatic diseases have an increased
risk for CVDs morbidity and mortality but the pathogenetic
factors involved are not yet fully understood. MetS may pro-
vide an additional link between accelerated atherosclerosis
and inflammation in these diseases [2] (Figure 1).
The great majority of these studies demonstrated that
the prevalence of MetS is higher in rheumatological diseases
than in the control populations, suggesting that either the
presence or the treatment of those diseases seems to influence
the risk of developing metabolic syndrome [18]. MetS is not
uncommon in patients with RA [19]. The risk of having
moderate-to-severe RAwas higher in patientswithMetS than
in thosewithoutMetS, and the disease activity correlatedwith
the number of MetS parameters present. Thus, MetS might
have inflammatory milieu leading to the occurrence of more
severe RA [20]. In studies evaluating the association of MetS
and RA, the prevalence of MetS is higher in RA subjects, but
the values vary according to the MetS criteria used [21, 22].
A different approach was developed by Crowson et al. The
authors noticed that a more clinically relevant question was
whether the prevalence of MetS is increased in RA subjects
without overt CVD. In fact, they observed higher prevalence
ofMetS inRA subjects (33%) comparedwith non-RA subjects
(25%) [23].
The increase of fat mass is also related to the occurrence
of OA and to the plethora of cardiovascular comorbidities.
Regarding the influence of fat mass on OA, it is evident that
biomechanical aspects are of weight in the pathogenesis of
diseases. Biomechanical loading is necessary for the mainte-
nance of cartilage homeostasis. However, abnormal loading is
associated with inflammatory and metabolic imbalances, in
part because it triggers the same signaling pathways as those
induced by inflammatory cytokines [24]. Chondrocytes sense
mechanical stress through ion channels, integrin-mediated
connections to the extracellular matrix, and intracellular or
membrane deformation [25]. However, OA is more common
in women [26, 27] and exists in non-weight-bearing joints
[28], indicating that a metabolic component is also present
[29]. Of late, OA and MetS have been related to each other.
The prevalence of MetS is higher in OA subjects [30, 31].
Recently, Zhuo et al. proposed a theory focused on inflamma-
tion, oxidative stress, common metabolites, and endothelial
dysfunction to link metabolic OA aetiologically to MetS.
They suggest that metabolic OA should be a new facet of
the definition of MetS, supported by its strong associations
and shared mechanisms with MetS components. However,
further research is needed to define the reciprocal influence
of OA on the currently accepted components of MetS [32].
A link between SLE and MetS also exists. Most of the
reports showed major prevalence of MetS in lupus patients
than in healthy controls. MetS is also common in young
patients with recently diagnosed SLE [33]. Moreover, subjects
with SLE and MetS presented higher levels of inflammatory
markers than SLE without MetS [34–36]. SLE patients also
have a higher risk of experiencing CVDs and metabolic
disorders related to MetS may contribute to overall CVD risk
[37].
The link between MetS and rheumatic diseases is also at
play in AS. It has been reported that AS patients have risk of
experiencingMetS andCVDs than in healthy controls (45.8%
versus 10.5%) [38], even after receiving anti-tumor necrosis
factor (anti-TNF) therapy [39]. Moreover, in these patients,
MetS was associated with higher disease activity.
Several features of MetS, such as dyslipidemia, have also
been reported, with higher prevalence in Sjögren’s syndrome.
It is noteworthy that metabolic alterations were associated
with a differentiated pattern of clinical and immunologi-
cal Sjögren’s syndrome expression but not with Sjögren’s
syndrome-related therapies (except for the higher frequency
of T2DM observed in patients treated with corticosteroids)
[40].
3. Adipokines and Metabolic Syndrome
White adipose tissue (WAT) is described as an endocrine
organ, which secretes a wide variety of factors called
adipokines. Adipokines are pleiotropic molecules that con-
tribute to the so-called low-grade inflammatory state of obese
subjects creating a cluster of metabolic aberrations including
autoimmune and inflammatory diseases that affect joints
and bone [41, 42]. Recent studies show a potential source
of adipokines at articular level: the infrapatellar fat pad
(IPFP). Actually, recent evidence indicates an inflammatory
phenotype of this adipose compartment in patients with OA
showing that IPFP could contribute to the pathophysiological
changes in the OA joint via the local production of cytokines
and adipokines [43]. In the majority of obese patients, a
dysfunctional adipose tissue mechanistically links obesity to
other manifestations such as CVDs and MetS. This dysfunc-
tion is caused by complex disequilibriumbetween genetic and
environmental factors, which is characterized by adipocyte
hypertrophy, hypoxia, and inflammation. The direct con-
sequence of this dysfunction is that adipokine secretion
is shifted to an atherogenic, diabetogenic, and proinflam-
matory secretion pattern. According to the recent litera-
ture, all known adipokines are markedly dysregulated when
abnormal abdominal fat accumulation is present, thereby
promotingmetabolic and cardiovascular disorders (Figure 1).
Adipokines were recently proposed as novel biomarkers
and regulators of MetS, given the association of adipokines
plasma concentration and MetS [44]. Among the different
adipokines, leptin and adiponectin were identified as relevant
factors involved in interactions between metabolism and
rheumatic disorders. Recent research suggests that leptin
may be an important factor linking obesity, the metabolic
syndrome, and cardiovascular disorders [45]. Additionally,
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Figure 1: Schematic representation of the relations between adipokines, cardiovascular diseases, and rheumatoid arthritis.
several clinical observations support an association between
adiponectin levels and obesity-related metabolic dysfunction
[46]. Given the recent pieces of evidence about the influence
of adipokines in both metabolic disorders and rheumatic
diseases, here we present an update summary of the main fat
mass induced adipokines as key players inMetS and themost
relevant rheumatic diseases.
4. Leptin
Leptin is a 16 kDa nonglycosylated hormone that belongs to
the class 1 cytokine superfamily. It is encoded by the obese
(ob) gene, the murine homolog of human LEP gene [47].
Leptin exerts its biological actions through the activation of
OB-Rb long-form isoform receptors encoded by the diabetes
(db) gene. It is mainly produced by adipocytes, and its
circulating levels positively correlate with WAT mass and
body mass index (BMI). Leptin levels are mostly dependent
on the amount of body fat, but its synthesis is also regulated
by inflammatory mediators [48]. It decreases food intake and
increases energy consumption by acting on specific hypotha-
lamic nuclei, inducing anorexigenic factors and suppressing
orexigenic neuropeptides [49].
4.1. Leptin and Metabolic Syndrome. Leptin was associated
with MetS. Subjects with MetS had higher leptin levels com-
pared with individuals without MetS. Furthermore, leptin
was strongly correlated with waist circumference and insulin
sensitivity [50]. Quercioli et al. observed that the decrease
in leptin plasma levels with decreasing body weight was
not observed to be related to the improvement in coronary
circulatory function [51]. This observation may emphasize
that beneficial effect of leptin plasma levels on endothelium-
related coronary function may operate predominantly in
morbidly obese individuals with a sevenfold increase of
its concentration to counterbalance the adverse effects of
obesity on coronary circulatory dysfunction as they are
previously described [52]. Noteworthy, leptin levels predict
MetS development independent of obesity.This association is
specifically related to the development of glucose intolerance
and insulin resistance [53]. Recent works support this rela-
tionship. Chiu et al. have observed how leptin concentrations
varied in relation to MetS score in both genders in Taiwanese
adults [54]. In another study, leptin showed significant
positive correlation with parameters of insulin resistance
and with triglycerides and strong negative correlation with
HDL-cholesterol [55]. Insulin resistance and changes in lipid
parameters are typical for early signs ofMetS. Kontunen et al.
assessed leptin levels in patientswith arthritis andMetS.Their
results showed higher leptin levels in subjects with arthritis
and MetS than arthritis patients without MetS [56]. This
suggests that leptin is associated with MetS but not directly
with arthritis, although a marked increase in plasma levels of
leptin in patients with RAwas noted [57]. Leptin resistance is
believed to be a major factor leading toMetS.The term leptin
resistance is used to describe the failure of obesity-related
hyperleptinemia to reduce food intake and increase energy
expenditure, at which point MetS is present [58] (Figure 2).
4.2. Leptin and Rheumatic Diseases. Leptin has been associ-
ated with rheumatic diseases due to its ability to modulate
bone and cartilage metabolism [59, 60]. This adipokine plays
main role in certain autoimmune diseases such as rheumatoid
arthritis (RA). Generally, the present consensus is that leptin
levels are elevated in patients with RA. However, in patients
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Figure 2: Schematic representation of adipokines actions in metabolic syndrome.
with RA undergoing anti-TNF-𝛼 therapy, no immediate
change in serum leptin levels was observed [61] (Table 1).
Several authors have also reported that the ratio between
serum leptin levels and the synovial fluid (SF) is correlated
with disease duration and parameters of RA activity [62].
Leptin has been supposed to play a part in RA although it is
still unclear whether leptin can damage or protect joint struc-
tures in RA. In fact, this hormone, generally considered to
be proinflammatory, has also been reported to be associated
with reduced radiographic joint damage [63], and this effect
could be related to anabolic effects of leptin [64]. The effects
of leptin in RA are not only related to articular tissues. Leptin
alsomodulates the activity ofmultiple immune cells [65].The
ability of leptin to induce regulatory T-cells anergy and T-cell
receptor hyporesponsiveness has gained much interest since
altered functioning of this cell type was described in RA [66].
Leptin has also been related to osteoarthritis (OA) and
cartilage metabolism. Recently, the NEIRID group showed
that leptin expression was higher in infrapatellar fat pad
(IPFP) and synovial tissues obtained from OA patients com-
pared to healthy controls [43]. Furthermore, chondrocytes
from human OA cartilage produce much more leptin than
those from normal cartilage [64]. In fact, the expression
pattern of leptin was related to the grade of cartilage
destruction [64], with the highest levels of leptin in the
advanced stages of the disease [72, 73]. Leptin could per-
petuate cartilage-degrading processes by inducing VCAM-1
expression, adhesion molecule responsible for leukocyte and
monocyte infiltration at inflamed joints [74]. In addition,
leptin induces IL-8 secretion in humanprimary chondrocytes
contributing to the chemotactic gradient seen in inflamed
joints [75]. Leptin is necessary for the development and
progression of OA associated with obesity. Impaired leptin
signalling associated with extreme obesity induces alterations
in subchondral bone morphology but without increasing the
incidence of OA [76]. These results suggest that obesity, per
se, is not sufficient to induce OA.
The role of leptin in SLE is controversial. Nowadays, most
of the studies suggest a role for leptin in this disease. Several
authors found higher leptin levels in SLE patients compared
with healthy controls, even after BMI correction [36, 77, 78].
Interestingly, in some of these studies, the hyperleptinemia
was associated with CVDs and with several features of MetS
[36, 78]. On the other hand, other groups have described
lower or unchanged circulating leptin levels in SLE patients
compared to healthy control [79, 80].
The role of leptin in ankylosing spondylitis (AS) is
still unclear and the data available are almost limited. For
instance, certain studies have not found any correlation
between serum leptin concentrations and markers of disease
activity [81, 82]. However, other authors determined an asso-
ciation among serum leptin levels, CRP, IL-6, and markers of
disease activity [83, 84].
5. Adiponectin
Adiponectin is a 244-residue protein, also known as GBP28,
apM1, Acrp30, or AdipoQ. It has structural homology with
collagen VIII, collagen X, and complement factor C1q.
Adiponectin acts via two receptors, one (AdipoR1) found
predominantly in skeletal muscle and the other (AdipoR2) in
liver. Transduction of the adiponectin signal by AdipoR1 and
AdipoR2 involves the activation of AMPK, PPAR-𝛼, PPAR-
𝛾, and other signaling molecules. Adiponectin is mainly
synthesized by adipose tissue in different molecular forms.
Circulating adiponectin levels tend to be low in obese patients
and increase with weight loss [85, 86]. It increases fatty acid
oxidation and glucose uptake in the muscle and reduces the
synthesis of glucose in the liver. Ablation of the adiponectin
gene has no dramatic effect in knockout mice on a normal
diet, but when placed on a high fat/sucrose diet, they develop
severe insulin resistance and exhibit lipid accumulation in
muscles [85].
5.1. Adiponectin and Metabolic Syndrome. Unlike most other
adipokines, plasma levels of adiponectin are decreased in
obesity and related pathologies, including T2DM and CVDs
[87–89]. Adiponectin levels are inversely proportional to
obesity and insulin resistance, increasingwithweight loss and
with the use of insulin-sensitizing drugs [85]. Its secretion
is inhibited by proinflammatory cytokines [90], suggesting
that inflammation might be an important factor contribut-
ing to hypoadiponectinemia in insulin-resistant and obese
states [91]. On the other hand, physical training increases
circulating adiponectin and expression of its receptors [92].
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Table 1: Major adipokines and the effect of anti-TNF-𝛼 therapy.
Adipokines RA Anti-TNF-𝛼 therapy Reference
Leptin ↑ or (—) No effect in serum levels [64]
Adiponectin ↑ No effect [67]
Visfatin ↑ Reduction in serum levels [68, 69]
Not variation [70]
Resistin ↑ Reduction in serum levels [69, 71]
Furthermore, dyslipidemia is also associated with low cir-
culating levels of adiponectin, even in the absence of other
MetS risk factors [93]. Recently, many studies have proposed
adiponectin as a MetS biomarker. Bae et al. reported a strong
negative correlation between MetS score and serum levels
[94] (Figure 2). In subjects with nascent MetS (without con-
founding T2DM and/or CVDs), adiponectin concentration
was lower than in controls [95]. Kim et al., in a prospective
cohort study, stated that decreasing levels of adiponectin
were progressively associated with increased incidence of
MetS [96]. Of late, the serum/plasma leptin: adiponectin ratio
(L : A) has been reported to be associated with dyslipidemia
and insulin resistance [97]. Kotani and Sakane suggested
that the L : A ratio can serve as a clinically useful marker
for detecting MetS characteristics in the general Japanese
population [98]. From the historical cohort of the Brisighella
Heart Study, Cicero et al. observed that subjects withoutMetS
had significantly lower L : A ratio than those with MetS [99].
In other study, Kontunen et al. assessed adiponectin levels in
patients with arthritis and MetS. Their results showed lower
adiponectin levels in subjects with arthritis and MetS than
arthritis patients without MetS [56]. Furthermore, Gonzalez-
Gay et al. suggested that low circulating adiponectin levels
may be implicated in the development of CVD associ-
ated with RA. They observed that in patients with RA
undergoing anti-TNF-𝛼 therapy, high-grade inflammation
was independently and negatively correlated with circulat-
ing adiponectin concentrations. However, the interaction of
high-grade inflammation with low circulating adiponectin
concentrations was not likely to be TNF-𝛼 mediated in RA
[100] (Table 1).
5.2. Adiponectin and Rheumatic Diseases. In contrast to its
previously described protective role in CVDs and obesity,
there are multiple lines of evidence that adiponectin acts
as a proinflammatory factor in joints and it could be
involved in matrix degradation. In cultured chondrocytes,
adiponectin stimulates the secretion of proinflammatory
mediators (iNOS, IL-6, and IL-8) [75, 101] and increases
MMP-3 expression [102]. Adiponectin levels have been found
to be higher in RA patients than in healthy controls [57, 63,
67, 103, 104]. Recently, it has been reported that adiponectin
and adiponectin receptor-1 expression are higher in synovial
fluids and the synovial tissues of RA patients compared
with controls, confirming the correlation of circulating
adiponectin levels with the severity of RA [67]. Recent
studies showed that adiponectin might also contribute to
synovitis and joint destruction in RA by stimulating MMP-
1 and MMP-13 [105]. Moreover, Frommer et al. described
that the different isoforms of adiponectin can induce the
expression of different genes involved in the pathogenesis of
RA [106], further demonstrating that adiponectin could have
detrimental effects on RA pathology.
Adiponectin is also implicated in the pathogenesis of
OA. It has been reported that plasma and serum levels of
adiponectin were significantly higher in OA patients than
in healthy controls [107, 108] and correlate with disease
severity [109]. In addition, adiponectin induces VCAM-1
expression [74] and IL-8 secretion [75] in human primary
chondrocytes, contributing to, respectively, the leukocyte
and monocyte infiltration and the chemotactic gradient seen
in inflamed joints. However, some data analyzing the role
of adiponectin in OA are controversial. Adiponectin has
been shown to inhibit IL-1b-induced MMP-13 expression
and to upregulate TIMP-2 production in chondrocytes [110].
Moreover, in STR/Ortmice, a spontaneous animalOAmodel,
serum adiponectin levels were lower compared with the
control group [111], suggesting a protective role for this
adipokine in the development and/or progression of the
disease. However, only a few clinical data support the hypoth-
esis that adiponectin could be a protective molecule against
OA. One study revealed an inverse correlation between
adiponectin and disease severity [112]. Moreover, another
recent study showed that serum adiponectin levels were
not associated with radiographic hand OA severity [113].
These contradictory results can be explained by differences in
patient characteristics and study protocols. It is also possible
that the significance of adiponectin varies according to the
phase and severity of the OA process.
Concerning the role of adiponectin in SLE, several studies
have showed elevated levels of this adipokine in SLE patients
[77, 79, 114]. Nevertheless, other authors did not find any
difference in adiponectin levels between SLE patients and
controls [78, 115]. However, the same authors find increased
MetS prevalence among subjects with SLE and low levels
of adiponectin in SLE patients with insulin resistance (IR)
compared to SLE subjects without IR, confirming the results
by Sada et al. [77, 78]. It also has been reported that mice
with experimental lupus, that lack adiponectin, developmore
severe disease than wild-type mice, suggesting the involve-
ment of adiponectin in regulating disease activity [116].
Little is known about the role of adiponectin in other
rheumatic diseases, such as AS and Sjögren’s syndrome.
However, it has been reported that serum adiponectin levels
are not different between AS patients and healthy controls
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[82]. Regarding Sjögren’s syndrome, it has been described that
adiponectin is expressed in salivary gland epithelial cells and
this expression is higher in patients with Sjögren’s syndrome
[117].
6. Visfatin
Visfatin is a protein of approximately 471 amino acids and
52 kDa, also called PBEF (pre-B cell colony enhancing fac-
tor) and NAMPT (nicotinamide phosphoribosyltransferase)
[118]. It was originally discovered in liver, bone marrow, and
muscle, but it is also secreted by macrophages and visceral
adipose tissue [119–121]. A specific receptor for visfatin has
not been identified yet. It has been reported that visfatin is
increased in obesity [122]. Moreover, leucocytes from obese
patients produce higher amounts of visfatin compared with
lean subjects [123]. It is supposed that visfatin has insulin
mimetic properties; however, the role of this adipokine
in glucose metabolism is still unclear and controversial
[120]. Visfatin synthesis is regulated by factors such as
glucocorticoids, TNF-𝛼, IL-6, and growth hormone (GH).
Moreover, visfatin has been shown to induce chemotaxis and
the production of IL-1𝛽, TNF-𝛼, and IL-6 in lymphocytes
from obese patients, suggesting potential involvement in the
obesity-associated inflammatory state [122].
6.1. Visfatin and Metabolic Syndrome. The relation of visfatin
with MetS is still confusing, but some studies have addressed
this issue. Several authors have shown that serum visfatin was
increased in subjects diagnosed with obesity, type-2 diabetes
mellitus, and MetS [124]. However, other studies have not
detected this relation. De Luis et al. reported that in a sample
of 826 female obese subjects, 42.4% had MetS. Their findings
showed that serum visfatin was correlated with total choles-
terol and C-reactive protein. However, in the multivariate
analysis, only C-reactive protein remained associated with
serum visfatin and serum visfatin was not associated with
the accumulation of MetS factors or the diagnosis of MetS
[125]. Specifically, in obesewomen,Olszanecka-Glinianowicz
et al. did not find a relation between visfatin levels and
the presence of MetS. Nevertheless, these authors suggest
that the proportion of the circulating visfatin and insulin
molecules, expressed as the visfatin/insulin ratio, more than
visfatin alone would be a good indicator for prevention of
the development of insulin resistance and MetS in the obese
[126]. In another approach, Bremer and Jialal investigated the
levels of visfatin in plasma and in subcutaneous fat (SAT),
finding no difference betweenMetS and control subjects [95].
Further studies are needed to analyse this unclear topic area,
because visfatin could be a proinflammatory factor favoring
the development of insulin resistance, as it was proposed [127]
(Figure 2).
6.2. Visfatin and Rheumatic Diseases. Recent findings sug-
gest, in arthritis animal models, that visfatin might act as a
relevant regulator of the inflammation and joint destruction.
In fact, it has been reported that serum and SF levels of
visfatin were increased in arthritis models [128–130]. Clinical
data also suggest a role for visfatin in the development
of RA. The NEIRID group and others demonstrated that
serum visfatin concentrations were higher in RA patients
compared with healthy controls [57, 63, 131, 132]. Moreover,
an association between serumvisfatin levels and radiographic
joint damage has been described [63, 133]. By contrast, the
relationship between visfatin and disease activity presents
conflicting results. Although Alkady et al. reported an asso-
ciation between these two parameters [131], others did not
find any correlation [132, 134]. Results obtained from trials
treating RA patients with anti-TNF-𝛼 therapy also present
some discrepancies. Several authors described a reduction
in visfatin levels upon anti-TNF-𝛼 therapy [132, 135], but
others did not show any variation [134] (Table 1). However,
all the data presented showed that visfatin participates in
RA pathology, even if the exact mechanisms by which this
adipokine exerts its proinflammatory and catabolic actions
are not completely understood.
At cartilage level, human OA chondrocytes produce vis-
fatin. This adipokine increases the expression of ADAMTS4,
ADAMTS5, MMP-3, and MMP-13, which are very relevant
cartilage degradative enzymes [136]. Moreover, OA patients
had higher synovial fluid visfatin concentrations, which are
correlated with degradation biomarkers such as collagen type
II and aggrecan [68]. Taken together, these data indicate that
visfatin develops catabolic functions at cartilage level and it
could play an important role in the pathophysiology of OA.
Studies performed in SLE and AS patients present con-
flicting results. Some authors determined higher visfatin
levels in SLE patients than in healthy controls [114], but others
did not found any variation between patients and controls
[137]. Similarly, there was no association between visfatin
levels and disease activity in both SLE and AS [81, 137].
7. Resistin
Resistin is also known asADSF (adipocyte-secreted factor) or
FIZZ3 (found in inflammatory zone 3). It is a 12.5 kDa protein
that belongs to the resistin-like molecules (RELMs) family
[70]. The major source of resistin in mice is white adipose
tissue (WAT) [69], whereas, in humans, it is predominantly
expressed in macrophages [138]. Thus, in human adipose
tissue, resistin is mainly produced by nonadipocyte resident
inflammatory cells [139]. Resistin receptor remains unknown,
but recently TLR4 was proposed to mediate resistin inflam-
matory responses in human cells [140]. Serum resistin levels
increase with obesity in mice, rats, and humans [141, 142]. In
animalmodels, resistin promotes insulin resistance, while the
evidence for this effect in human is less clear [70, 143], so that
it was proposed as potential link between obesity and diabetes
[70].
7.1. Resistin and Metabolic Syndrome. In humans, data on the
role of this adipokine in insulin sensitivity and obesity are
controversial [144]. Some authors indicated that increased
serum resistin levels are associated with increased obesity,
visceral fat [70], insulin resistance, and T2DM, while other
groups failed to observe such correlations [145]. Recent
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investigations have attempted to shed light on the debate
[146, 147]. As MetS by itself is associated with inflammation,
there might be the possibility that resistin is rather associated
with inflammation markers that would appear at different
stages of MetS development and its correlation with other
metabolic and anthropometric parameters like glucose, blood
lipids, and BMI is just a secondary effect [148]. Whether
resistin is an active player or merely a responder in metabolic
dysfunction cannot be fully determined without understand-
ing the regulation of resistin itself. Genetic determinants
of resistin expression may provide additional clues about
the role of resistin in human susceptibility to disease [149]
(Figure 2).
7.2. Resistin and Rheumatic Diseases. Until now, a significant
difference was not found in serum resistin levels between
RA patients and healthy controls [57, 150]. However, a role
for resistin has been proposed and its involvement in RA
pathology was explored [151]. Recombinant resistin increases
the production of several proinflammatory cytokines, and
the intra-articular injection of this adipokine in the knee
joints of mice causes arthritis [151]. In humans, there is also
evidence for a role of resistin in RA pathology. Anti-TNF
drugs reduced serum resistin levels [135, 152] (Table 1), but no
association has been found between resistin concentrations
and radiographic progression [133]. By contrast, there are
several studies that report an association between resistin
and markers of inflammation such as C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR), IL- 6, IL-1RA,
or leukocyte count in RA patients [56, 150, 153]. Further-
more, resistin has been correlated with disease activity and
joint destruction [153], and synovial fluid samples from
RA patients showed higher levels of this adipokine than
those from OA patients [151, 153], suggesting that resistin is
produced in the inflamed joint.
8. Other Adipokines
8.1. Lipocalin-2. Lipocalin-2 (LCN2), also known as sidero-
calin, 24p3, uterocalin, and neutrophil gelatinase-associated
lipocalin (NGAL), is a 25 kDa glycoprotein isolated from
neutrophil granules, although WAT is thought to be the
main source [154]. This adipokine is believed to bind small
lipophilic substances, such as steroids and LPS [155], and has
been reported to have roles in the induction of apoptosis
in hematopoietic cells [156], transport of fatty acids [71],
modulation of inflammation [157], and metabolic homeosta-
sis [158]. LCN2 expression is altered in several pathologic
conditions, such as adipose tissue hypoxia and obesity [158,
159]. Nevertheless, whether lipocalin-2 plays a role in the
pathogenesis of obesity-related diseases has not been inves-
tigated so far.
Recent studies have reported the association between
serum LCN2 concentrations and various metabolic param-
eters and inflammatory markers [158, 160, 161]. The study of
Jang et al. provides the first clinical evidence demonstrating
that serum concentrations of LCN2 are closely associated
with obesity and its related chronic inflammation and
metabolic complications. Patients with MetS showed higher
levels of LCN2 than thosewithoutMetS.However, correlation
between serum LCN2 concentration and the number of
MetS components was not significant. Nonetheless, they
suggest serum LCN2 as a useful biomarker for evaluating
the outcomes in various clinical settings of obesity-related
metabolic and cardiovascular disease [162].
LCN2 is expressed in different types of cells and it has
been identified in chondrocytes [163]. In these cells, LCN2
expression was modulated by IL-1𝛽, leptin, adiponectin, LPS,
and dexamethasone [164]. In addition, the synovial fluid
from patients with knee OA was found to be enriched with
MMP-9/LCN2 complexes that have been involved in matrix
degradation [165]. Recently, the group of Katano confirmed
that synovial fluid levels of LCN2 were significantly higher
in patients with RA than in those with OA. Through a
proteome analysis, they showed that granulocytemacrophage
colony-stimulating factor (GM-CSF) can contribute to the
pathogenesis of RA by upregulating LCN2 in neutrophils,
followed by the induction of a series of enzymes, such
as cathepsin D, transitional endoplasmic reticulum ATPase
(TERA), and transglutaminase 2 (tg2) in synoviocytes, which
could contribute to the proliferation of synovial cells and
infiltration of inflammatory cells inside the synovium [166].
Accordingly, lipocalin may regulate immune cell recruitment
to the site of inflammation, a process essential for the con-
trolled initiation, perpetuation, and resolution of inflamma-
tory processes [167]. Finally, very recently, the NEIRID group
had showed that nitric oxide boosts TLR-4mediated lipocalin
expression in chondrocytes, suggesting the existence of a
feedback loop regulating the expression of this adipokine
[168].
8.2. Chemerin. Chemerin, also known as TIG2 (tazarotene-
induced gene 2) or RARRES2 (retinoic acid receptor respon-
der 2), is an adipokine with chemoattractant activity. It is
secreted as an 18 kDa inactive proprotein and it is activated
by posttranslational C-terminal cleavage. Chemerin acts via
the G-protein-coupled receptor chemokine-like receptor 1
(CMKLR1 or ChemR23) [169]. Chemerin and its receptor are
mainly, but not exclusively, expressed in adipose tissue [170]
and, for instance, dendritic cells and macrophages express
chemerin receptor [171]. It has been implicated in immune
[169] and metabolic homeostasis [170]. Chemerin expression
correlates with BMI in humans and is upregulated in the
adipose tissue of obese and T2DM sand rats (Psammomys
obesus) [170]. IL-1𝛽 has been reported to induce chemerin
expression in mouse adipocytes [172].
Bozaoglu et al. identified, for the first time, chemerin
as a novel adipokine, which may play a role in the patho-
physiology of obesity and MetS. They showed that plasma
chemerin concentrations were strongly associated with BMI,
plasma triglycerides, and blood pressure. These findings
suggest that chemerin may play an important role in obesity
and MetS. Moreover, it raises the possibility that chemerin
may be of value as a biomarker for this disorder [108].
Recently, two studies determine chemerin levels in plasma
and subcutaneous adipose tissue (SAT) in nascent MetS
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patients, without concomitant diabetes or CVD. In their
studies, theymade the observation that both plasma and SAT
levels of chemerin were higher in subjects with nascentMetS,
suggesting an early role of chemerin in the pathogenesis of
MetS [95, 173].
Interestingly, chondrocytes express chemerin and its
receptor [164, 174], and IL-1𝛽 is able to increase chemerin
expression [164]. In the same way, Berg et al. have demon-
strated that recombinant chemerin enhances the production
of several proinflammatory cytokines (TNF-𝛽𝛼, IL-1𝛽, IL-
6, and IL-8), as well as different MMPs (MMP-1, MMP-
2, MMP-3, MMP-8, and MMP-13), in human articular
chondrocytes [174]. These factors have a role in the joint
inflammation and degradation of the extracellular matrix by
causing breakdown of the collagen and aggrecan framework
and result in irreversible destruction of the cartilage in OA
and RA. Furthermore, chemerin was recently detected in
synovial fluid from OA and RA patients [175, 176]. The
serumconcentration of this adipokine correlatedwith disease
severity in OA [176] and with disease activity in RA [177].
8.3. Omentin. Omentin is a 40 kDa protein secreted by
omental adipose tissue that has previously been identified
as intelectin, a new type of Ca2+-dependent lectin. It is
highly and selectively expressed in visceral adipose tis-
sue, and that might regulate insulin action by increasing
insulin-mediated glucose uptake in human subcutaneous and
omental adipocytes [178]. Plasma omentin levels and gene
expression in adipose tissue decrease with obesity and cor-
relate positively with plasma adiponectin and high-density
lipoprotein levels and negatively with waist circumference,
BMI, and insulin levels, all of which are markers of MetS
[179]. Expression of the omentin gene was demonstrated
in omental adipose tissue of patients with Crohn’s disease,
suggesting a role in chronic inflammatory diseases [180].
In two different studies, the group of Bremer determined
omentin levels in nascent MetS patients. They observed
that both plasma and subcutaneous adipose tissue levels of
omentinwere lower in subjects with nascentMetS, suggesting
that lower secretion of omentin from SAT in subjects with
nascent MetS establishes the presence of omentin deficiency
in the syndrome as well [95, 173].
More recently, Šenolt et al. have demonstrated reduced
levels of omentin in the synovial fluid of patients with RA
comparedwith thosewithOA [181].This finding suggests that
this adipokine is likely to be involved in OA pathophysiology.
9. Conclusions
The relationships among metabolic syndrome, adipokines,
and rheumatic diseases are complex, encompassing a vari-
ety of influences that include also cardiovascular function,
metabolic status, biomechanics, and also behavioural aspects.
A critical aspect that we have always borne in mind is that
MetS is closely related to inflammation or chronic “low-
grade inflammatory state” that will influence heavily the
courses of rheumatic diseases. Thus, the first line approach
to tackle MetS is the prevention of excessive weight gain
across lifespan. Of course, this kind of approach should
not be an individual task but rather should be a social
priority. However, this strategy, in order to be effective, might
require deep sociocultural changes, as well as international
coordinated social instructions that right now are really far
from being achieved.
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forms: a potential therapeutic target in rheumatoid arthritis?”
Annals of the Rheumatic Diseases, vol. 71, no. 10, pp. 1724–1732,
2012.
[107] T. B. Laurberg, J. Frystyk, T. Ellingsen et al., “Plasma
adiponectin in patients with active, early, and chronic
rheumatoid arthritis who are steroid- and disease-modifying
antirheumatic drug-naive compared with patients with
osteoarthritis and controls,” Journal of Rheumatology, vol. 36,
no. 9, pp. 1885–1891, 2009.
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Zórad, and M. Stanćıková, “Alterations in adipocyte glucose
transporter GLUT4 and circulating adiponectin and visfatin
in rat adjuvant induced arthritis,” General Physiology and
Biophysics, vol. 29, no. 1, pp. 79–84, 2010.
[131] E. A. M. Alkady, H. M. Ahmed, L. Tag, and M. A. Abdou,
“Serum and synovial adiponectin, resistin, and visfatin levels
in rheumatoid arthritis patients. Relation to disease activity,”
Zeitschrift für Rheumatologie, vol. 70, no. 7, pp. 602–608, 2011.
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